lymphoma

[Signal Transduction and Targeted Therapy] Via an unbiased genome-wide CRISPR/Cas9 screening, scientists identified loss of NOXA, a B-cell lymphoma 2 family protein in B cell malignancies, as a pivotal regulator of resistance to CAR T cell therapy by impairing apoptosis of tumor cells both in vitro and in vivo.

[US FDA] The FDA approved axicabtagene ciloleucel for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.

[AVM Biotechnology, LLC (Business Wire)] AVM Biotechnology, LLC, announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant. This $1.6 million award from the National Institute of Diabetes and Digestive Kidney Disease will allow the company to pursue additional research in the use of AVM0703 as a monotherapy and combination therapy to reverse recent onset and established Type 1 Diabetes.

[Cell Death Discovery] Scientists found that specific deletion of Cbl-b and c-Cbl in CD11c+ cells, predominantly in dendritic cells (DCs), led to liver fibrosis, cirrhosis, and accumulation of systemic conventional Type I DCs due to enhanced cell proliferation and decreased cell apoptosis.

[Nature Biotechnology] The authors described an implantable Multifunctional Alginate Scaffold for T Cell Engineering and Release that streamlined in vivo CAR-T cell manufacturing and reduced processing time to a single day.

[Pediatric Blood & Cancer] While the majority of patients with complete responses to the brentuximab vedotin with gemcitabine regimen ultimately underwent high-dose chemotherapy and autologous stem cell transplantation (ASCT) consolidation, four subjects, reported herein, achieved durable complete remissions lasting more than four years after the study treatment but without ASCT consolidation.